18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

E. Zamagni, C. Nanni, F. Gay, A. Pezzi, F. Patriarca, M. Bellò, I. Rambaldi, P. Tacchetti, J. Hillengass, B. Gamberi, L. Pantani, V. Magarotto, A. Versari, M. Offidani, B. Zannetti, F. Carobolante, M. Balma, P. Musto, M. Rensi, K. MancusoA. Dimitrakopoulou-Strauss, S. Chauviè, S. Rocchi, N. Fard, G. Marzocchi, G. Storto, P. Ghedini, A. Palumbo, S. Fanti, M. Cavo

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide 18 F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16% of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38% of patients progressed to MM, in a median time of 4 years, including 21% with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95% confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58% for positive versus 33% for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalLeukemia
Volume30
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Multiple Myeloma
Osteolysis
Radioisotopes
Bone Marrow
Electrons
Confidence Intervals
Glucose

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Zamagni, E., Nanni, C., Gay, F., Pezzi, A., Patriarca, F., Bellò, M., ... Cavo, M. (2016). 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia, 30(2), 417-422. https://doi.org/10.1038/leu.2015.291

18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. / Zamagni, E.; Nanni, C.; Gay, F.; Pezzi, A.; Patriarca, F.; Bellò, M.; Rambaldi, I.; Tacchetti, P.; Hillengass, J.; Gamberi, B.; Pantani, L.; Magarotto, V.; Versari, A.; Offidani, M.; Zannetti, B.; Carobolante, F.; Balma, M.; Musto, P.; Rensi, M.; Mancuso, K.; Dimitrakopoulou-Strauss, A.; Chauviè, S.; Rocchi, S.; Fard, N.; Marzocchi, G.; Storto, G.; Ghedini, P.; Palumbo, A.; Fanti, S.; Cavo, M.

In: Leukemia, Vol. 30, No. 2, 01.02.2016, p. 417-422.

Research output: Contribution to journalArticle

Zamagni, E, Nanni, C, Gay, F, Pezzi, A, Patriarca, F, Bellò, M, Rambaldi, I, Tacchetti, P, Hillengass, J, Gamberi, B, Pantani, L, Magarotto, V, Versari, A, Offidani, M, Zannetti, B, Carobolante, F, Balma, M, Musto, P, Rensi, M, Mancuso, K, Dimitrakopoulou-Strauss, A, Chauviè, S, Rocchi, S, Fard, N, Marzocchi, G, Storto, G, Ghedini, P, Palumbo, A, Fanti, S & Cavo, M 2016, '18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease', Leukemia, vol. 30, no. 2, pp. 417-422. https://doi.org/10.1038/leu.2015.291
Zamagni, E. ; Nanni, C. ; Gay, F. ; Pezzi, A. ; Patriarca, F. ; Bellò, M. ; Rambaldi, I. ; Tacchetti, P. ; Hillengass, J. ; Gamberi, B. ; Pantani, L. ; Magarotto, V. ; Versari, A. ; Offidani, M. ; Zannetti, B. ; Carobolante, F. ; Balma, M. ; Musto, P. ; Rensi, M. ; Mancuso, K. ; Dimitrakopoulou-Strauss, A. ; Chauviè, S. ; Rocchi, S. ; Fard, N. ; Marzocchi, G. ; Storto, G. ; Ghedini, P. ; Palumbo, A. ; Fanti, S. ; Cavo, M. / 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. In: Leukemia. 2016 ; Vol. 30, No. 2. pp. 417-422.
@article{0a04467264d44a638a2dcb66bbfeb824,
title = "18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease",
abstract = "Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide 18 F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16{\%} of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38{\%} of patients progressed to MM, in a median time of 4 years, including 21{\%} with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95{\%} confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58{\%} for positive versus 33{\%} for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.",
author = "E. Zamagni and C. Nanni and F. Gay and A. Pezzi and F. Patriarca and M. Bell{\`o} and I. Rambaldi and P. Tacchetti and J. Hillengass and B. Gamberi and L. Pantani and V. Magarotto and A. Versari and M. Offidani and B. Zannetti and F. Carobolante and M. Balma and P. Musto and M. Rensi and K. Mancuso and A. Dimitrakopoulou-Strauss and S. Chauvi{\`e} and S. Rocchi and N. Fard and G. Marzocchi and G. Storto and P. Ghedini and A. Palumbo and S. Fanti and M. Cavo",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/leu.2015.291",
language = "English",
volume = "30",
pages = "417--422",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

AU - Zamagni, E.

AU - Nanni, C.

AU - Gay, F.

AU - Pezzi, A.

AU - Patriarca, F.

AU - Bellò, M.

AU - Rambaldi, I.

AU - Tacchetti, P.

AU - Hillengass, J.

AU - Gamberi, B.

AU - Pantani, L.

AU - Magarotto, V.

AU - Versari, A.

AU - Offidani, M.

AU - Zannetti, B.

AU - Carobolante, F.

AU - Balma, M.

AU - Musto, P.

AU - Rensi, M.

AU - Mancuso, K.

AU - Dimitrakopoulou-Strauss, A.

AU - Chauviè, S.

AU - Rocchi, S.

AU - Fard, N.

AU - Marzocchi, G.

AU - Storto, G.

AU - Ghedini, P.

AU - Palumbo, A.

AU - Fanti, S.

AU - Cavo, M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide 18 F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16% of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38% of patients progressed to MM, in a median time of 4 years, including 21% with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95% confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58% for positive versus 33% for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.

AB - Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrated with computed tomography (PET/CT) using glucose labelled with the positron-emitting radionuclide 18 F) allows for assessing early skeletal involvement. Identification of osteolytic lesions by this technique has recently been incorporated into the updated International Myeloma Working Group criteria for MM diagnosis. However, no data are available regarding the impact of focal lesions (FLs) without underlying osteolysis on time to progression (TTP) to MM. We hence prospectively studied a cohort of 120 SMM patients with PET/CT. PET/CT was positive in 16% of patients (1 FL: 8, 2 FLs: 3, >3 FLs: 6, diffuse bone marrow involvement: 2). With a median follow-up of 2.2 years, 38% of patients progressed to MM, in a median time of 4 years, including 21% with skeletal involvement. The risk of progression of those with positive PET/CT was 3.00 (95% confidence interval 1.58-5.69, P=0.001), with a median TTP of 1.1 versus 4.5 years for PET/CT-negative patients. The probability of progression within 2 years was 58% for positive versus 33% for negative patients. In conclusion, PET/CT positivity significantly increased the risk of progression of SMM to MM. PET/CT could become a new tool to define high-risk SMM.

UR - http://www.scopus.com/inward/record.url?scp=84959353184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959353184&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.291

DO - 10.1038/leu.2015.291

M3 - Article

C2 - 26490489

AN - SCOPUS:84959353184

VL - 30

SP - 417

EP - 422

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -